{"id":"mirikizumab-mir","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":{"setId":"472cbe04-263e-433d-9a0f-58c1b50b715a","title":"OMVOH (MIRIKIZUMAB-MRKZ) INJECTION, SOLUTION OMVOH (MIRIKIZUMAB-MRKZ) KIT [ELI LILLY AND COMPANY]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-23 is a key cytokine involved in the differentiation and expansion of pro-inflammatory T cells, particularly Th17 cells. By blocking the p19 subunit of IL-23, mirikizumab prevents IL-23-mediated immune activation and reduces pathogenic inflammation. This mechanism is particularly relevant in conditions driven by IL-23-dependent immune responses, such as inflammatory bowel disease.","oneSentence":"Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:01:32.304Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT06249555","phase":"","title":"VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study","status":"RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2024-03-20","conditions":"Crohn's Disease","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Omvoh"],"phase":"marketed","status":"active","brandName":"Mirikizumab (MIR)","genericName":"Mirikizumab (MIR)","companyName":"Alimentiv Inc.","companyId":"alimentiv-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mirikizumab is a monoclonal antibody that selectively inhibits the IL-23 p19 subunit, reducing IL-23 signaling in immune cells to suppress inflammatory responses. Used for Ulcerative colitis, Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}